(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Atossa Therapeutics, Inovio Pharmaceuticals, and Nano Dimension.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Atossa Therapeutics (ATOS) | 1.17 | 22.51% | 2023-06-28 23:46:07 |
| 2 | Inovio Pharmaceuticals (INO) | 0.47 | 21.78% | 2023-06-29 14:48:33 |
| 3 | Nano Dimension (NNDM) | 2.76 | 14.32% | 2023-06-29 14:37:58 |
| 4 | Aemetis (AMTX) | 6.50 | 10.54% | 2023-06-28 19:42:07 |
| 5 | Astrotech Corporation (ASTC) | 14.20 | 9.23% | 2023-06-28 23:06:08 |
| 6 | American Superconductor Corporation (AMSC) | 6.08 | 8.77% | 2023-06-28 19:15:07 |
| 7 | MicroVision (MVIS) | 3.92 | 8.15% | 2023-06-29 14:34:25 |
| 8 | Nikola (NKLA) | 1.25 | 7.76% | 2023-06-29 14:52:50 |
| 9 | Upland Software (UPLD) | 3.61 | 7.61% | 2023-06-29 14:36:10 |
| 10 | BlackBerry (BB) | 5.38 | 7.29% | 2023-06-29 13:47:24 |
The three biggest losers today are Virgin Galactic, Biocept, and Biolase.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Virgin Galactic (SPCE) | 4.25 | -10.44% | 2023-06-29 13:47:05 |
| 2 | Biocept (BIOC) | 1.16 | -10.08% | 2023-06-29 05:07:09 |
| 3 | Biolase (BIOL) | 0.07 | -8.61% | 2023-06-29 05:08:09 |
| 4 | Aptose Biosciences (APTO) | 4.59 | -8.57% | 2023-06-28 21:09:08 |
| 5 | Ascent Solar Technologies (ASTI) | 0.13 | -7.59% | 2023-06-28 23:08:07 |
| 6 | Bio-Path Holdings (BPTH) | 1.63 | -7.39% | 2023-06-29 07:48:07 |
| 7 | Cara Therapeutics (CARA) | 2.86 | -5.73% | 2023-06-29 11:12:08 |
| 8 | Brainstorm Cell Therapeutics (BCLI) | 2.00 | -5.66% | 2023-06-29 03:12:08 |
| 9 | Baidu (BIDU) | 133.94 | -5.54% | 2023-06-29 14:46:09 |
| 10 | McCormick & Company (MKC) | 86.83 | -5.46% | 2023-06-29 14:58:00 |
Winners today
1. Atossa Therapeutics (ATOS) – 22.51%
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
NASDAQ ended the session with Atossa Therapeutics rising 22.51% to $1.17 on Thursday while NASDAQ fell 0% to $13,591.33.
Earnings Per Share
As for profitability, Atossa Therapeutics has a trailing twelve months EPS of $-0.21.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.91%.
Volume
Today’s last reported volume for Atossa Therapeutics is 5854230 which is 846.33% above its average volume of 618624.
Yearly Top and Bottom Value
Atossa Therapeutics’s stock is valued at $1.17 at 17:32 EST, under its 52-week high of $1.22 and way above its 52-week low of $0.50.
More news about Atossa Therapeutics.
2. Inovio Pharmaceuticals (INO) – 21.78%
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
NASDAQ ended the session with Inovio Pharmaceuticals jumping 21.78% to $0.47 on Thursday, after five successive sessions in a row of losses. NASDAQ slid 0% to $13,591.33, after two sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-0.89.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -87.1%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Inovio Pharmaceuticals’s stock is considered to be overbought (>=80).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Inovio Pharmaceuticals’s EBITDA is -7.74.
Revenue Growth
Year-on-year quarterly revenue growth declined by 42.3%, now sitting on 10.18M for the twelve trailing months.
More news about Inovio Pharmaceuticals.
3. Nano Dimension (NNDM) – 14.32%
Nano Dimension Ltd., together with its subsidiaries, provides additive electronics in Israel and internationally. The company offers 3D printers, comprising DragonFly IV that produces Hi-PEDs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components; digital light processing printers (DLP) that achieves production-grade polymer and composite parts; and admaflex that utilizes a patented DLP foil system that fabricates ceramic and metal parts. It also provides additive electronics robotics and control systems, which includes surface-mount-technology, an electronics assembly equipment for electronic components on Hi-PEDs and PCBs, catering to various manufacturing and volume requirements; and ink delivery systems controls electronics, software, and ink delivery systems for digital printing. In addition, the company offers software to provide engineers with the tools to bring precision and electrical parts from design-to-manufacturing, as well as sells various materials that are developed in-house. Nano Dimension Ltd. was incorporated in 1960 and is headquartered in Ness Ziona, Israel.
NASDAQ ended the session with Nano Dimension jumping 14.32% to $2.76 on Thursday, after three sequential sessions in a row of gains. NASDAQ slid 0% to $13,591.33, after two consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, Nano Dimension has a trailing twelve months EPS of $-0.9.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.3%.
Volume
Today’s last reported volume for Nano Dimension is 8549220 which is 377.63% above its average volume of 1789910.
Previous days news about Nano Dimension
- : nano dimension raises stratasys cash buyout bid back above $20 a share. According to MarketWatch on Tuesday, 27 June, "Back on June 13, Nano Dimension had recommitted to the $18-per-share bid to buy Stratasys originally submitted on March 22, after raising the bid to $20.05 a share in April. ", "Separately, Nano Dimension reiterated its first-quarter revenue outlook of $14.97 million. "
More news about Nano Dimension.
4. Aemetis (AMTX) – 10.54%
Aemetis, Inc. operates as a renewable natural gas and renewable fuels company in North America and India. It operates through three segments: California Ethanol, Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the acquisition, development, and commercialization of negative carbon intensity products and technologies that replace traditional petroleum-based products. It sells biodiesel primarily to government oil marketing companies, transport companies, resellers, distributors, and private refiners through its own sales force and independent sales agents, as well as to brokers who resell the product to end-users. The company also produces and sells ethanol; and wet distillers grains, distillers corn oil, and condensed distillers solubles to dairies and feedlots as animal feed. In addition, it produces dairy biogas; produces and sells high-grade alcohol and various feed products, as well as hand sanitizers; and researches and develops conversion technologies using waste feedstocks to produce biofuels and biochemicals. The company was formerly known as AE Biofuels, Inc. and changed its name to Aemetis, Inc. in November 2011. Aemetis, Inc. was founded in 2005 and is headquartered in Cupertino, California.
NASDAQ ended the session with Aemetis jumping 10.54% to $6.50 on Thursday while NASDAQ fell 0% to $13,591.33.
Earnings Per Share
As for profitability, Aemetis has a trailing twelve months EPS of $-3.38.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 3800% and positive 42.6% for the next.
Volume
Today’s last reported volume for Aemetis is 917693 which is 29.01% below its average volume of 1292720.
More news about Aemetis.
5. Astrotech Corporation (ASTC) – 9.23%
Astrotech Corporation operates as a mass spectrometry company worldwide. It owns and licenses the intellectual property related to the Astrotech Mass Spectrometer Technology, a platform mass spectrometry technology. The company also develops TRACER 1000, a mass spectrometer-based explosive trace detector to replace the explosives trace detectors used at airports, cargo and other secured facilities, and borders. In addition, it develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. Further, the company develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. Astrotech Corporation was incorporated in 1984 and is based in Austin, Texas.
NASDAQ ended the session with Astrotech Corporation jumping 9.23% to $14.20 on Thursday while NASDAQ fell 0% to $13,591.33.
Earnings Per Share
As for profitability, Astrotech Corporation has a trailing twelve months EPS of $-5.73.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.3%.
More news about Astrotech Corporation.
6. American Superconductor Corporation (AMSC) – 8.77%
American Superconductor Corporation, together with its subsidiaries, provides megawatt-scale power resiliency solutions worldwide. The company operates in two segments, Grid and Wind. The Grid segment offers products and services that enable electric utilities, industrial facilities, and renewable energy project developers to connect, transmit, and distribute power under the Gridtec Solutions brand; and engineering planning services. It provides transmission planning services, which identify power grid congestion, poor power quality, and other risks; grid interconnection solutions for wind farms and solar power plants, power quality systems, and transmission and distribution cable systems; resilient electric grid systems, resilient electric grid systems; D-VAR systems used for controlling power flow and voltage in the AC transmission system; actiVAR system, a fast-switching medium-voltage reactive compensation solution; armorVAR system installed for reactive compensation, power factor correction, loss reduction, utility bill savings, and mitigation of common power quality concerns related to power converter-based generation and load devices; and D-VAR volt var optimization (VVO) that serves the distribution power grid market. This segment also offers ship protection systems, which reduce a naval ship's magnetic signature; and in board power delivery systems, power generation systems, and propulsion systems; and transformers and rectifiers systems. The Wind segment designs wind turbine systems and licenses these designs to third parties under the Windtec Solutions brand. It supplies power electronics and software-based control systems, engineered designs, and support services; and provides customer support services to wind turbine manufacturers. This segment's design portfolio comprises a range of drivetrains and power ratings of 2 megawatts and higher. The company was incorporated in 1987 and is headquartered in Ayer, Massachusetts.
NASDAQ ended the session with American Superconductor Corporation jumping 8.77% to $6.08 on Thursday, following the last session’s upward trend. NASDAQ dropped 0% to $13,591.33, after two successive sessions in a row of gains, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, American Superconductor Corporation has a trailing twelve months EPS of $-1.2.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.66%.
Yearly Top and Bottom Value
American Superconductor Corporation’s stock is valued at $6.08 at 17:32 EST, way below its 52-week high of $7.58 and way higher than its 52-week low of $3.20.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.1%, now sitting on 105.98M for the twelve trailing months.
More news about American Superconductor Corporation.
7. MicroVision (MVIS) – 8.15%
MicroVision, Inc. develops and sells lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module supporting AR headsets; interactive display solutions for the smart speakers market; and Consumer Lidar used in smart home systems. In addition, it develops 1st Generation LRL module. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.
NASDAQ ended the session with MicroVision jumping 8.15% to $3.92 on Thursday while NASDAQ dropped 0% to $13,591.33.
Earnings Per Share
As for profitability, MicroVision has a trailing twelve months EPS of $-0.33.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -62.05%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 25% and a negative 37.5%, respectively.
Volatility
MicroVision’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.81%, a negative 0.65%, and a positive 5.92%.
MicroVision’s highest amplitude of average volatility was 3.81% (last week), 8.69% (last month), and 5.92% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MicroVision’s stock is considered to be overbought (>=80).
More news about MicroVision.
8. Nikola (NKLA) – 7.76%
Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions. It operates through two business units, Truck and Energy. The Truck business unit develops and commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. The Energy business unit develops and constructs a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. The company also assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.
NASDAQ ended the session with Nikola jumping 7.76% to $1.25 on Thursday, following the last session’s upward trend. NASDAQ slid 0% to $13,591.33, after two consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, Nikola has a trailing twelve months EPS of $-1.72.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -137.05%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 489.1%, now sitting on 60.05M for the twelve trailing months.
Volatility
Nikola’s last week, last month’s, and last quarter’s current intraday variation average was a negative 6.27%, a positive 3.70%, and a positive 7.67%.
Nikola’s highest amplitude of average volatility was 9.90% (last week), 9.99% (last month), and 7.67% (last quarter).
More news about Nikola.
9. Upland Software (UPLD) – 7.61%
Upland Software, Inc. provides cloud-based enterprise work management software in the United States, the United Kingdom, Canada, and internationally. It offers a family of software applications under the Upland brand in the areas of marketing, sales, contact center, project management, information technology, business operations, and human resources and legal. The company also provides professional services, such as implementation, data extraction, integration and configuration, and training services, as well as customer support services. It serves large global corporations, various government agencies, and small and medium-sized businesses, as well as financial, consulting, technology, manufacturing, media, telecommunication, political, healthcare, life sciences, and retail and hospitality sectors. The company was formerly known as Silverback Enterprise Group, Inc. and changed its name to Upland Software, Inc. in November 2013. Upland Software, Inc. was incorporated in 2010 and is headquartered in Austin, Texas.
NASDAQ ended the session with Upland Software jumping 7.61% to $3.61 on Thursday while NASDAQ dropped 0% to $13,591.33.
Earnings Per Share
As for profitability, Upland Software has a trailing twelve months EPS of $-6.45.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.96%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 58.2% and a negative 52%, respectively.
Yearly Top and Bottom Value
Upland Software’s stock is valued at $3.61 at 17:32 EST, way under its 52-week high of $15.77 and way higher than its 52-week low of $2.73.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Upland Software’s EBITDA is 1.53.
Volatility
Upland Software’s last week, last month’s, and last quarter’s current intraday variation average was 1.99%, 0.82%, and 3.42%.
Upland Software’s highest amplitude of average volatility was 2.74% (last week), 3.83% (last month), and 3.42% (last quarter).
More news about Upland Software.
10. BlackBerry (BB) – 7.29%
NYSE ended the session with BlackBerry rising 7.29% to $5.38 on Thursday, after two consecutive sessions in a row of losses. NYSE jumped 0.75% to $15,734.20, following the last session’s downward trend on what was a somewhat up trend trading session today.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BlackBerry’s stock is considered to be oversold (<=20).
Volatility
BlackBerry’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.56%, a negative 0.17%, and a positive 2.32%.
BlackBerry’s highest amplitude of average volatility was 3.21% (last week), 1.72% (last month), and 2.32% (last quarter).
Sales Growth
BlackBerry’s sales growth is negative 4.6% for the current quarter and negative 2% for the next.
Previous days news about BlackBerry
- Blackberry (bb) beats Q1 earnings and revenue estimates. According to Zacks on Wednesday, 28 June, "While BlackBerry has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
More news about BlackBerry.
Losers Today
1. Virgin Galactic (SPCE) – -10.44%
Virgin Galactic Holdings, Inc. focuses on the development, manufacture, and operation of spaceships and related technologies for conducting commercial human spaceflight and flying commercial research and development payloads into space. It is also involved in the ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The company serves private individuals, researchers, and government agencies. Virgin Galactic Holdings, Inc. was founded in 2017 is headquartered in Las Cruces, New Mexico.
NYSE ended the session with Virgin Galactic dropping 10.44% to $4.25 on Thursday, after four successive sessions in a row of gains. NYSE jumped 0.75% to $15,734.20, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, Virgin Galactic has a trailing twelve months EPS of $-1.63.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Virgin Galactic’s stock is considered to be oversold (<=20).
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 20.9% and positive 12.7% for the next.
Volume
Today’s last reported volume for Virgin Galactic is 84974400 which is 369.05% above its average volume of 18116100.
Volatility
Virgin Galactic’s last week, last month’s, and last quarter’s current intraday variation average was a negative 7.53%, a positive 1.36%, and a positive 5.28%.
Virgin Galactic’s highest amplitude of average volatility was 10.75% (last week), 6.65% (last month), and 5.28% (last quarter).
More news about Virgin Galactic.
2. Biocept (BIOC) – -10.08%
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
NASDAQ ended the session with Biocept dropping 10.08% to $1.16 on Thursday while NASDAQ slid 0% to $13,591.33.
Earnings Per Share
As for profitability, Biocept has a trailing twelve months EPS of $-55.26.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -187.65%.
Yearly Top and Bottom Value
Biocept’s stock is valued at $1.16 at 17:32 EST, way under its 52-week high of $36.00 and above its 52-week low of $1.14.
Revenue Growth
Year-on-year quarterly revenue growth declined by 96.6%, now sitting on 6.59M for the twelve trailing months.
More news about Biocept.
3. Biolase (BIOL) – -8.61%
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
NASDAQ ended the session with Biolase sliding 8.61% to $0.07 on Thursday, after five consecutive sessions in a row of losses. NASDAQ dropped 0% to $13,591.33, after two successive sessions in a row of gains, on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Biolase has a trailing twelve months EPS of $-3.57.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -206.6%.
Sales Growth
Biolase’s sales growth is 25.5% for the present quarter and 45.7% for the next.
Yearly Top and Bottom Value
Biolase’s stock is valued at $0.07 at 17:32 EST, way under its 52-week high of $5.94 and way higher than its 52-week low of $0.06.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Biolase’s EBITDA is 0.33.
More news about Biolase.
4. Aptose Biosciences (APTO) – -8.57%
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
NASDAQ ended the session with Aptose Biosciences sliding 8.57% to $4.59 on Thursday while NASDAQ slid 0% to $13,591.33.
Earnings Per Share
As for profitability, Aptose Biosciences has a trailing twelve months EPS of $-6.99.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -96.45%.
Yearly Top and Bottom Value
Aptose Biosciences’s stock is valued at $4.59 at 17:32 EST, way under its 52-week high of $6.60 and way higher than its 52-week low of $0.36.
Moving Average
Aptose Biosciences’s value is way above its 50-day moving average of $2.15 and way higher than its 200-day moving average of $1.00.
Volume
Today’s last reported volume for Aptose Biosciences is 86980 which is 60.14% below its average volume of 218235.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 21.8% and a negative 11.5%, respectively.
More news about Aptose Biosciences.
5. Ascent Solar Technologies (ASTI) – -7.59%
Ascent Solar Technologies, Inc. designs, manufactures, and sells copper-indium-gallium-diselenide photovoltaic products for aerospace, defense, emergency management, and consumer/OEM applications. It offers outdoor solar chargers. The company markets and sells its products through OEMs, system integrators, distributors, retailers, and e-commerce companies. Ascent Solar Technologies, Inc. was incorporated in 2005 and is based in Thornton, Colorado.
NASDAQ ended the session with Ascent Solar Technologies falling 7.59% to $0.13 on Thursday, following the last session’s downward trend. NASDAQ fell 0% to $13,591.33, after two sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, Ascent Solar Technologies has a trailing twelve months EPS of $-0.62.
Volume
Today’s last reported volume for Ascent Solar Technologies is 1210380 which is 29.12% below its average volume of 1707680.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Ascent Solar Technologies’s EBITDA is 17.15.
Moving Average
Ascent Solar Technologies’s value is way under its 50-day moving average of $0.18 and way under its 200-day moving average of $1.67.
Yearly Top and Bottom Value
Ascent Solar Technologies’s stock is valued at $0.13 at 17:32 EST, way under its 52-week high of $11.50 and way above its 52-week low of $0.10.
More news about Ascent Solar Technologies.
6. Bio-Path Holdings (BPTH) – -7.39%
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
NASDAQ ended the session with Bio-Path Holdings dropping 7.39% to $1.63 on Thursday, following the last session’s downward trend. NASDAQ slid 0% to $13,591.33, after two sequential sessions in a row of gains, on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Bio-Path Holdings has a trailing twelve months EPS of $-2.65.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -100.45%.
Volume
Today’s last reported volume for Bio-Path Holdings is 53353 which is 62.61% above its average volume of 32809.
Yearly Top and Bottom Value
Bio-Path Holdings’s stock is valued at $1.63 at 17:32 EST, way under its 52-week high of $4.48 and way higher than its 52-week low of $1.18.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 4.8% and positive 14.3% for the next.
Moving Average
Bio-Path Holdings’s value is above its 50-day moving average of $1.56 and way below its 200-day moving average of $1.97.
More news about Bio-Path Holdings.
7. Cara Therapeutics (CARA) – -5.73%
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
NASDAQ ended the session with Cara Therapeutics falling 5.73% to $2.86 on Thursday, following the last session’s downward trend. NASDAQ fell 0% to $13,591.33, after two successive sessions in a row of gains, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, Cara Therapeutics has a trailing twelve months EPS of $-1.67.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -49.54%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 575% and a negative 18.6%, respectively.
Yearly Top and Bottom Value
Cara Therapeutics’s stock is valued at $2.86 at 17:32 EST, way under its 52-week high of $12.98 and higher than its 52-week low of $2.77.
Sales Growth
Cara Therapeutics’s sales growth is negative 70.3% for the present quarter and 7.6% for the next.
Volume
Today’s last reported volume for Cara Therapeutics is 1526800 which is 20.14% above its average volume of 1270840.
More news about Cara Therapeutics.
8. Brainstorm Cell Therapeutics (BCLI) – -5.66%
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
NASDAQ ended the session with Brainstorm Cell Therapeutics sliding 5.66% to $2.00 on Thursday while NASDAQ fell 0% to $13,591.33.
Earnings Per Share
As for profitability, Brainstorm Cell Therapeutics has a trailing twelve months EPS of $-0.62.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -497.07%.
Yearly Top and Bottom Value
Brainstorm Cell Therapeutics’s stock is valued at $2.00 at 17:32 EST, way below its 52-week high of $4.70 and way above its 52-week low of $1.09.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 21.1% and 21.1%, respectively.
Volume
Today’s last reported volume for Brainstorm Cell Therapeutics is 186728 which is 45.06% below its average volume of 339925.
More news about Brainstorm Cell Therapeutics.
9. Baidu (BIDU) – -5.54%
Baidu, Inc. offers internet search services in China. It operates through Baidu Core and iQIYI segments. The company offers Baidu App to access search, feed, and other services using mobile devices; Baidu Search to access its search and other services; Baidu Feed that provides users with personalized timeline based on their demographics and interests; Baidu Health that helps users to find the doctor and hospital for healthcare needs; and Haokan, a short video app. It also provides Baidu Knows, an online community where users can ask questions to other users; Baidu Wiki; Baidu Experience; Baidu Post; Baidu Wenku; Baidu Maps, a voice-enabled mobile app that provides travel-related services; Baidu Drive; Baijiahao; and DuerOS, a smart assistant platform. In addition, it offers online marketing services, which include pay for performance, an auction-based services that allow customers to bid for priority placement of paid sponsored links and reach users who search for information related to their products or services; other marketing services that include display-based marketing services and other online marketing services based on performance criteria other than cost per click; mobile ecosystem, a portfolio of apps, including Baidu App, Haokan, and Baidu Post; various cloud services and solutions, such as platform as a service, software as a service, and infrastructure as a service; self-driving services, including maps, automated valet parking, navigation pilot, electric vehicles, and robotaxi fleets, as well as Xiaodu smart devices. Further, the company provides iQIYI, an online entertainment service, including original and licensed content; other video content and membership; and online advertising services. Baidu, Inc. has strategic partnership with Zhejiang Geely Holding Group. The company was formerly known as Baidu.com, Inc. Baidu, Inc. was incorporated in 2000 and is headquartered in Beijing, China.
NASDAQ ended the session with Baidu falling 5.54% to $133.94 on Thursday while NASDAQ fell 0% to $13,591.33.
Earnings Per Share
As for profitability, Baidu has a trailing twelve months EPS of $5.39.
PE Ratio
Baidu has a trailing twelve months price to earnings ratio of 24.85. Meaning, the purchaser of the share is investing $24.85 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.2%.
Yearly Top and Bottom Value
Baidu’s stock is valued at $133.94 at 17:32 EST, way under its 52-week high of $160.88 and way higher than its 52-week low of $73.58.
Sales Growth
Baidu’s sales growth is 13.4% for the present quarter and 4.3% for the next.
Volatility
Baidu’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.02%, a positive 0.58%, and a positive 2.19%.
Baidu’s highest amplitude of average volatility was 1.67% (last week), 2.15% (last month), and 2.19% (last quarter).
Moving Average
Baidu’s worth is above its 50-day moving average of $128.45 and above its 200-day moving average of $124.55.
More news about Baidu.
10. McCormick & Company (MKC) – -5.46%
McCormick & Company, Incorporated manufactures, markets, and distributes spices, seasoning mixes, condiments, and other flavorful products to the food industry. It operates in two segments, Consumer and Flavor Solutions. The Consumer segment offers spices, herbs, and seasonings, as well as condiments and sauces, and desserts. This segment markets its products under the McCormick, French's, Frank's RedHot, Lawry's, Cholula Hot Sauce, Gourmet Garden, Club House, and OLD BAY brands in the Americas; Ducros, Schwartz, Kamis, and LA Drogheria, and Vahiné brands in Europe, the Middle East, and Africa; McCormick and DaQiao brands in China; and McCormick, Aeroplane, and Gourmet Garden brands in Australia, as well as markets regional and ethnic brands, such as Zatarain's, Stubb's, Thai Kitchen, and Simply Asia. It also supplies its products under the private labels. This segment serves retailers comprising grocery, mass merchandise, warehouse clubs, discount and drug stores, and e-commerce retailers directly and indirectly through distributors and wholesale foodservice suppliers. The Flavor Solutions segment offers seasoning blends, spices and herbs, condiments, coating systems, and compound flavors to multinational food manufacturers and foodservice customers. It serves foodservice customers directly and indirectly through distributors. McCormick & Company, Incorporated was founded in 1889 and is headquartered in Hunt Valley, Maryland.
NYSE ended the session with McCormick & Company falling 5.46% to $86.83 on Thursday, after five sequential sessions in a row of losses. NYSE rose 0.75% to $15,734.20, following the last session’s downward trend on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, McCormick & Company has a trailing twelve months EPS of $2.47.
PE Ratio
McCormick & Company has a trailing twelve months price to earnings ratio of 35.16. Meaning, the purchaser of the share is investing $35.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.02%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 2.8%, now sitting on 6.39B for the twelve trailing months.
More news about McCormick & Company.
Stay up to date with our winners and losers daily report
